Results 51 to 60 of about 737,167 (335)

A common theme in interaction of bacterial immunoglobulin-binding proteins with immunoglobulins illustrated in the equine system [PDF]

open access: yes, 2008
The M protein of Streptococcus equi subsp. equi known as fibrinogen-binding protein (FgBP) is a cell wall-associated protein with antiphagocytic activity that binds IgG. Recombinant versions of the seven equine IgG subclasses were used to investigate the
Abi-Rached   +49 more
core   +4 more sources

Evaluation of disulfide bond position to enhance the thermal stability of a highly stable single domain antibody.

open access: yesPLoS ONE, 2014
Single domain antibodies are the small recombinant variable domains derived from camelid heavy-chain-only antibodies. They are renowned for their stability, in large part due to their ability to refold following thermal or chemical denaturation.
Dan Zabetakis   +4 more
doaj   +1 more source

Characterization and epitope mapping of human monoclonal antibodies to PDC-E2, the immunodominant autoantigen of primary biliary cirrhosis [PDF]

open access: yes, 1992
Further to define the epitopes of PDC-E2, the major autoantigen in primary biliary cirrhosis (PBC), we have developed and characterized five human monoclonal antibodies. These antibodies were derived by fusing a regional hepatic lymph node from a patient
Bassendine   +49 more
core   +1 more source

Nanobodies as tools to understand, diagnose, and treat African trypanosomiasis [PDF]

open access: yes, 2017
African trypanosomes are strictly extracellular protozoan parasites that cause diseases in humans and livestock and significantly affect the economic development of sub-Saharan Africa.
Caljon, Guy   +5 more
core   +1 more source

Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B Hemagglutinin

open access: yesAntibodies, 2019
Influenza B virus (IBV) circulates in the human population and causes considerable disease burden worldwide, each year. Current IBV vaccines can struggle to mount an effective cross-reactive immune response, as strains become mismatched, due to constant ...
Walter Ramage   +8 more
doaj   +1 more source

Construction of Novel Bispecific Single-Domain Antibodies (BiSdAbs) with Potent Antiangiogenic Activities

open access: yesPharmaceutical Fronts, 2020
The development of bispecific antibodies (BsAbs) has had a profound impact on cancer immunotherapy. Single-domain antibodies (SdAbs) could offer advantages over other antibody formats for the generation of a BsAbs, such as small size (∼12–15 kDa), with ...
Xianglei Liu   +3 more
doaj   +1 more source

Crosstalk between the ribosome quality control‐associated E3 ubiquitin ligases LTN1 and RNF10

open access: yesFEBS Letters, EarlyView.
Loss of the E3 ligase LTN1, the ubiquitin‐like modifier UFM1, or the deubiquitinating enzyme UFSP2 disrupts endoplasmic reticulum–ribosome quality control (ER‐RQC), a pathway that removes stalled ribosomes and faulty proteins. This disruption may trigger a compensatory response to ER‐RQC defects, including increased expression of the E3 ligase RNF10 ...
Yuxi Huang   +8 more
wiley   +1 more source

The mitochondrial receptor complex [PDF]

open access: yes, 1993
The receptor complex in the mitochondrial outer membrane, which consists of at least seven different proteins, is responsible for the recognition and translocation of cytosolically synthesized preproteins.
Alberts   +55 more
core   +4 more sources

Interplay between circadian and other transcription factors—Implications for cycling transcriptome reprogramming

open access: yesFEBS Letters, EarlyView.
This perspective highlights emerging insights into how the circadian transcription factor CLOCK:BMAL1 regulates chromatin architecture, cooperates with other transcription factors, and coordinates enhancer dynamics. We propose an updated framework for how circadian transcription factors operate within dynamic and multifactorial chromatin landscapes ...
Xinyu Y. Nie, Jerome S. Menet
wiley   +1 more source

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

open access: yesOncoImmunology, 2022
Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials ...
Antonio Tapia-Galisteo   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy